These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR. Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557 [Abstract] [Full Text] [Related]
4. Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma. Vose JM. Semin Oncol; 1996 Jun; 23(3 Suppl 6):33-7. PubMed ID: 8677446 [Abstract] [Full Text] [Related]
5. Non-Hodgkin's lymphomas: a review of the M.D. Anderson experience. Cabanillas F. Semin Oncol; 1992 Feb; 19(1 Suppl 1):11-3. PubMed ID: 1384134 [Abstract] [Full Text] [Related]
6. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival. van Besien K, Rodriguez A, Tomany S, Younes A, Donato M, Sarris A, Giralt S, Mehra R, Andersson B, Gajewski J, Champlin R, Cabanillas F. Bone Marrow Transplant; 2001 Feb; 27(4):397-404. PubMed ID: 11313669 [Abstract] [Full Text] [Related]
7. Ifosfamide in the treatment of non-Hodgkin's lymphoma. Pohlman B. Semin Oncol; 1996 Jun; 23(3 Suppl 6):27-32. PubMed ID: 8677445 [Abstract] [Full Text] [Related]
10. [High-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of non-Hodgkin's lymphoma]. Yamane T, Hino M, Ohta K, Koh KR, Nakamae H, Aoyama Y, Ota T, Kishida T, Mugitani A, Sannomiya Y, Kamitani T, Takubo T, Tatsumi N. Gan To Kagaku Ryoho; 2000 Sep; 27(10):1547-55. PubMed ID: 11016000 [Abstract] [Full Text] [Related]
11. A pilot study of CODOX-M/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma. A Scotland and Newcastle Lymphoma Group Study. Davidson KL, Devaney MB, Tighe JE, Rogers SY, Dunlop DJ, Mackie MJ, Thomas RV, Johnson PR, Scotland and Newcastle Lymphoma Group Study. Haematologica; 2003 Dec; 88(12):1366-71. PubMed ID: 14687989 [Abstract] [Full Text] [Related]
12. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, Ozet G, Zengin N. Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961 [Abstract] [Full Text] [Related]
13. How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term? Zinzani PL, Martelli M, Magagnoli M, Zaja F, Storti S, Pavone E, Lauta VM, De Renzo A, Gobbi M, Bocchia M, Ronconi F, Scaramucci L, Gherlinzoni F, Palombi F, Bendandi M, Stefoni V, Anticoli Borza P, Cellini C, Mandelli F, Tura S. Haematologica; 1999 Nov; 84(11):996-1001. PubMed ID: 10553159 [Abstract] [Full Text] [Related]
15. [Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hematology and Hemotherapy]. López-Guillermo A, García-Conde J, Alvarez-Carmona AM, León P, Maldonado J, Alcalá A, Zubizarreta A, Sancho-Tello R, Carbonell F, Contreras E, Besses C, Hernando A, Fontanillas M, Montserrat E. Med Clin (Barc); 1998 May 09; 110(16):601-4. PubMed ID: 9656196 [Abstract] [Full Text] [Related]
16. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL). Gobbi PG, Ghirardelli ML, Avanzini P, Baldini L, Quarta G, Stelitano C, Broglia C, Loni C, Silingardi V, Ascari E. Haematologica; 2000 Mar 09; 85(3):263-8. PubMed ID: 10702814 [Abstract] [Full Text] [Related]
17. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma. Mayer J, Vásová I, Korístek Z, Navrátil M, Klabusay M, Doubek M, Vorlícek J, Cernilová I, Vodvárka P, Petráková K. Eur J Haematol Suppl; 2001 Jul 09; 64():21-7. PubMed ID: 11486396 [Abstract] [Full Text] [Related]
18. Ifosfamide- and paclitaxel-based treatment of relapsed and refractory lymphoma. King K, Younes A. Semin Oncol; 2000 Feb 09; 27(1 Suppl 1):14-22. PubMed ID: 10697039 [Abstract] [Full Text] [Related]
19. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study. Rigacci L, Carrai V, Nassi L, Alterini R, Longo G, Bernardi F, Bosi A. Cancer; 2005 Mar 01; 103(5):970-7. PubMed ID: 15666323 [Abstract] [Full Text] [Related]
20. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation. Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E. Biol Blood Marrow Transplant; 2005 Sep 01; 11(9):688-97. PubMed ID: 16125639 [Abstract] [Full Text] [Related] Page: [Next] [New Search]